HAE Stock Analysis: Buy, Sell, or Hold?
HAE - Haemonetics Corporation
$56.24
-0.12 (-0.21%)
▼
5d:
+0.55%
30d:
-14.31%
90d:
-30.55%
HOLD
MODERATE Confidence
Analysis Updated: Apr 1, 2026 12:00 AM ET
Earnings: May 14, 2026
Get Alerted When HAE Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: HAE shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: HAE shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$92.38
Based on 5.8% avg growth
INTRINSIC VALUE TODAY
$57.36
2.0% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 13.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: HAE is currently trading at $56.24, which is considered oversold relative to its 30-day fair value range of $57.79 to $63.51. From a valuation perspective, the stock is trading at a discount (Forward PE: 10.6) compared to its historical average (13.1). Remarkably, the market is currently pricing in an annual earnings decline of 7.0% over the next few years. This pessimistic expectation contrasts with the company's recent 28.4% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, HAE is in a strong downtrend. Immediate support is located at $53.88, while resistance sits at $60.93.
Market Sentiment: HAE has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $87.50 (+55.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, HAE is in a strong downtrend. Immediate support is located at $53.88, while resistance sits at $60.93.
Market Sentiment: HAE has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $87.50 (+55.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$57.79 -
$63.51
Company Quality Score
48/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 55.6% below Wall St target ($87.50)
Fair Price Analysis
30-Day Fair Range
$57.79 -
$63.51
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$53.88
Resistance Level
$60.93
Current Trend
Strong Downtrend
Technical data as of
Apr 1, 2026
Fundamental Context
Forward P/E (Next Year Est.)
10.57
Wall Street Target
$87.50
(+55.6%)
Revenue Growth (YoY)
-2.7%
Earnings Growth (YoY)
28.4%
Profit Margin
13.3%
Valuation Discount vs History
-7.0% cheaper
PE vs Historical
10.6 vs 13.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.0%
(market-implied from PE analysis)
1-Year Target
$52.30
(-7%)
2-Year Target
$48.64
(-14%)
3-Year Target
$45.24
(-20%)
3-Yr Target (if PE normalizes)
(PE: 11→13)
$56.08
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.4, Growth: 7.6%)
$148.11
(+163%)
Base:
(SPY PE: 10.6, Growth: 7.6%)
$70.03
(+25%)
Bear:
(PE: 9.0, Growth: 7.6%)
$59.53
(+6%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (16x PE), but valuation improves significantly next year (11x PE) as earnings recover.
Trailing PE: 16.14 | Current EPS (TTM): $3.63
Bull Case
$94.47
(+62%)
Analyst growth 46.6%, PE expands to 17.8
Base Case
$85.88
(+47%)
Market implied 46.6%, PE stable at 16.1
Bear Case
$39.83
(-32%)
Severe decline -20.0%, PE contracts to 13.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.6 to 13.1
Stabilization Target:
$69.71
(+24.0%)
PE Expansion Potential:
+24.0%
Share & Embed Analysis
Last updated: April 02, 2026 9:06 AM ET
Data refreshes hourly during market hours. Next update: 10:06 AM
Data refreshes hourly during market hours. Next update: 10:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HAE showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Medical Devices Stocks
Top-rated stocks in Medical Devices by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BSX
Boston Scientific Corp |
STRONG BUY
34 analysts |
$102 | 61 BUY |
|
SYK
Stryker Corporation |
BUY
32 analysts |
$424 | 59 HOLD |
|
DXCM
DexCom Inc |
STRONG BUY
26 analysts |
$86 | 54 HOLD |
|
ABT
Abbott Laboratories |
BUY
28 analysts |
$133 | 59 HOLD |
|
MDT
Medtronic PLC |
BUY
32 analysts |
$111 | 63 BUY |
